Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy

International Journal of Cancer

Volumn 134, Issue 10, 2014, Pages 2437-2447

  Weller, Michael ^a   Kaulich, Kerstin ^b,c   Hentschel, Bettina ^d   Felsberg, Joerg ^b,c   Gramatzki, Dorothee ^a   Pietsch, Torsten ^e   Simon, Matthias ^e   Westphal, Manfred ^f   Schackert, Gabriele ^g   Tonn, Joerg C ^h   Von Deimling, Andreas ⁱ   Davis, Thomas ^j   Weiss, William Andrew ^k   Loeffler, Markus ^d   Reifenberger, Guido ^b,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY OF HAMBURG   (Germany)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j Celldex Therapeutics Inc   (United Kingdom)

^k USCF   (United States)

more..

Author keywords

EGFRvIII; epidermal growth factor receptor; glioblastoma; immunotherapy; prognosis; rindopepimut

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURGERY; COHORT ANALYSIS; DISEASE ASSOCIATION; EGFR GENE; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84895922426     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28576     Document Type: Article

References (35)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
2. Johnson DR, O'Neill BP,. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012; 107: 359-64.
3. Weller M, Pfister SM, Wick W, et al. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013; 14: e370-9.
4. Wen PY, Kesari S,. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
5. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild-type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010; 120: 707-18.
6. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
7. Gilbert MR WM, Aldape KD, Stupp R, et al. RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense(dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol 2011; 29 (suppl; abstr 2006).
8. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-50.
9. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13: 707-15.
10. Collins VP,. Amplified genes in human gliomas. Semin Cancer Biol 1993; 4: 27-32.
11. Brandes AA, Franceschi E, Tosoni A, et al. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res 2008; 14: 957-60.
12. Hegi ME, Rajakannu P, Weller M,. Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr Opin Neurol 2012; 25: 774-9.
13. Gan HK, Kaye AH, Luwor RB,. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009; 16: 748-54.
14. Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011; 13: 324-33.
15. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 4722-9.
16. Reifenberger J, Reifenberger G, Ichimura K, et al. Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol 1996; 149: 29-35.
17. Wang MY, Lu KV, Zhu S, et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006; 66: 7864-9.
18. Fan QW, Cheng C, Gustafson WC, et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell, 2013; 24:438-49.
19. Felsberg J, Rapp M, Loeser S, et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 2009; 15: 6683-93.
20. Aldape KD, Ballman K, Furth A, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004; 63: 700-7.
21. Ekstrand AJ, Sugawa N, James CD, et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 1992; 89: 4309-13.
22. Yoshimoto K, Dang J, Zhu S, et al. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res 2008; 14: 488-93.
23. Ohgaki H, Kleihues P,. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013; 19: 764-72.
24. von Deimling A, von Ammon K, Schoenfeld D, et al. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993; 3: 19-26.
25. Watanabe K, Tachibana O, Sata K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217-23.
26. Ruano Y, Ribalta T, de Lope AR, et al. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am J Clin Pathol 2009; 131: 257-63.
27. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63: 6962-70.
28. Montano N, Cenci T, Martini M, et al. Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia 2011; 13: 1113-21.
29. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005; 11: 1462-6.
30. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007; 25: 2288-94.
31. Crane CA, Ahn BJ, Han SJ, et al. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol 2012; 14: 584-95.
32. Biernat W, Huang H, Yokoo H, et al. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 2004; 14: 131-6.
33. Chakravarti A, Seiferheld W, Tu X, et al. Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005; 62: 318-27.
34. Jeuken J, Sijben A, Alenda C, et al. Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 2009; 19: 661-71.
35. Nishikawa R, Sugiyama T, Narita Y, et al. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol 2004; 21: 53-6.